Comparison tool

Semaglutide vs 5-Amino-1MQ side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

Semaglutide5-Amino-1MQ

Share this peptide comparison

Property	Semaglutide	5-Amino-1MQ
Category	Weight Loss	Weight Loss
Also known as	Ozempic, Wegovy, Rybelsus	5-amino-1-methylquinolinium, NNMT Inhibitor
FDA approved	Yes	No
Clinical status	FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Preclinical research; no published human trials reported in the supplied source Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Weight loss, appetite control, blood sugar management	Fat metabolism, cellular energy, body composition
How it works	According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.	5-Amino-1MQ is described in the supplied evidence as an inhibitor of NNMT, the enzyme nicotinamide N-methyltransferase. The proposed model is that lowering NNMT activity may affect adipocyte metabolism through nicotinamide, NAD+ and SAM-related pathways, potentially shifting energy handling in fat tissue. The cited mouse work reported increases in intracellular NAD+ and SAM after NNMT inhibition, but the source does not provide human trial confirmation for these effects.
Typical dosing	1-2.4 mg weekly (after titration) · Once weekly	50-75 mg daily · Once daily, morning · 4-6 weeks on, 2-4 weeks off
Research dosing	0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)	20 mg/kg/day (mice) · 4-6 weeks (cycling recommended) · Subcutaneous injection or oral
Typical duration	Long-term / chronic use	4-6 weeks (cycling recommended)
Administration	Subcutaneous injection weekly, or oral (Rybelsus)	Subcutaneous injection or oral
Timing	Morning, same day each week With or without food	Morning, fasted With or without food
Evidence level	FDA Approved	Preclinical
Possible side effects	Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.) Vomiting Diarrhea +10 more Constipation Abdominal pain Headache Fatigue Injection site reactions Hypoglycemia (Source associates this report with insulin/sulfonylureas.) Gallbladder problems Pancreatitis Acute kidney injury Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)	Mild headache (Reported with initial dosing in the supplied source.) Nausea (Listed as a reported side effect by the source.) Increased alertness or jitteriness (Source-reported; may relate to timing concerns about sleep disruption.) +2 more Insomnia (Listed as rare in the supplied source.) Elevated blood pressure (Listed as rare in the supplied source.)
Research summary	The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.	The supplied source highlights preclinical work on small-molecule NNMT inhibitors in diet-induced obese mice. In that work, treated animals reportedly lost about 5% of baseline weight over roughly 11 days, had lower white adipose mass and reduced circulating cholesterol, while food intake did not change. The source characterizes the overall evidence base as animal and cell research and states that published human trials demonstrating fat loss, increased energy expenditure or long-term safety were not available. The source separately cautions that vendor-promoted percentages for human fat loss remain unsupported by clinical trial evidence.
References	Source Source +2 more Source Source	Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Semaglutide

5-Amino-1MQ

Category

Weight Loss

Also known as

Ozempic, Wegovy, Rybelsus

5-amino-1-methylquinolinium, NNMT Inhibitor

FDA approved

Yes

Clinical status

FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Preclinical research; no published human trials reported in the supplied source

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Weight loss, appetite control, blood sugar management

Fat metabolism, cellular energy, body composition

How it works

According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.

5-Amino-1MQ is described in the supplied evidence as an inhibitor of NNMT, the enzyme nicotinamide N-methyltransferase. The proposed model is that lowering NNMT activity may affect adipocyte metabolism through nicotinamide, NAD+ and SAM-related pathways, potentially shifting energy handling in fat tissue. The cited mouse work reported increases in intracellular NAD+ and SAM after NNMT inhibition, but the source does not provide human trial confirmation for these effects.

Typical dosing

1-2.4 mg weekly (after titration) · Once weekly

50-75 mg daily · Once daily, morning · 4-6 weeks on, 2-4 weeks off

Research dosing

0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)

20 mg/kg/day (mice) · 4-6 weeks (cycling recommended) · Subcutaneous injection or oral

Typical duration

Long-term / chronic use

4-6 weeks (cycling recommended)

Administration

Subcutaneous injection weekly, or oral (Rybelsus)

Subcutaneous injection or oral

Timing

Morning, same day each week

With or without food

Morning, fasted

With or without food

Evidence level

FDA Approved

Preclinical

Possible side effects

Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.)
Vomiting
Diarrhea

+10 more

Constipation
Abdominal pain
Headache
Fatigue
Injection site reactions
Hypoglycemia (Source associates this report with insulin/sulfonylureas.)
Gallbladder problems
Pancreatitis
Acute kidney injury
Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)

Mild headache (Reported with initial dosing in the supplied source.)
Nausea (Listed as a reported side effect by the source.)
Increased alertness or jitteriness (Source-reported; may relate to timing concerns about sleep disruption.)

+2 more

Insomnia (Listed as rare in the supplied source.)
Elevated blood pressure (Listed as rare in the supplied source.)

Research summary

The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.

The supplied source highlights preclinical work on small-molecule NNMT inhibitors in diet-induced obese mice. In that work, treated animals reportedly lost about 5% of baseline weight over roughly 11 days, had lower white adipose mass and reduced circulating cholesterol, while food intake did not change. The source characterizes the overall evidence base as animal and cell research and states that published human trials demonstrating fat loss, increased energy expenditure or long-term safety were not available. The source separately cautions that vendor-promoted percentages for human fat loss remain unsupported by clinical trial evidence.

References

Source Source

+2 more

Source Source

Full profile

View Details